Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma

Part of paid clinical trials in Nashville, Tennessee.

Sponsor
SCRI Development Innovations, LLC
Study ID
NCT00193505
Phase
PHASE2
Status
Completed

Conditions

  • Non-Hodgkins Lymphoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Ifosfamide — DRUG
  • Carboplatin — DRUG
  • Etoposide — DRUG
  • Rituximab — DRUG
  • 90Y Zevalin — DRUG

Study Details

In this Multicenter trial, we will evaluate the feasibility, toxicity, and efficacy of treatment with 90Y Zevalin following a short course of salvage chemotherapy in patients with relapsed/refractory intermediate grade B-cell non-Hodgkin's lymphoma.

Key Dates

First listed
Sep 19, 2005
Start date
Oct 31, 2003
Status verified
May 2011
Primary completion
Aug 31, 2005
Completion
Aug 31, 2005

Study Design

Enrollment
40 participants
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

complete response rate

Locations (1)

FacilityCityStateZIPSite coordinators
Tennessee Oncology, PLLCNashvilleTennessee37023-

Find similar trials in Nashville, TN

By research site
Tennessee Oncology, PLLC· Nashville, TN

Related Studies